SOLV

Company Overview — What Does Solventum Corp Do?

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota. Solventum Corp (SOLV) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Bryan C. Hanson and employs approximately 22,000 people, headquartered in ST. PAUL, Minnesota. With a market capitalization of $11.2B, SOLV is one of the prominent companies in the Healthcare sector.

Solventum Corp (SOLV) Stock Rating — Reduce (April 2026)

As of April 2026, Solventum Corp receives a Reduce rating with a composite score of 44.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SOLV ranks #2,279 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Solventum Corp ranks #267 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SOLV Stock Price and 52-Week Range

Solventum Corp (SOLV) currently trades at $65.79. The stock lost $0.39 (0.6%) in the most recent trading session. The 52-week high for SOLV is $88.20, which means the stock is currently trading -25.4% from its annual peak. The 52-week low is $60.70, putting the stock 8.4% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.

Is SOLV Overvalued or Undervalued? — Valuation Analysis

Solventum Corp (SOLV) carries a value factor score of 77/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 6.71x, compared to the Healthcare sector average of 23.63x — a discount of 72%. The price-to-book ratio stands at 2.15x, versus the sector average of 2.75x. The price-to-sales ratio is 1.29x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, SOLV trades at 6.81x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, Solventum Corp appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

Solventum Corp Profitability — ROE, Margins, and Quality Score

Solventum Corp (SOLV) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 32.0%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 11.3% versus the sector average of -33.1%.

On a margin basis, Solventum Corp reports gross margins of 54.6%, compared to 71.5% for the sector. The operating margin is 27.8% (sector: -66.1%). Net profit margin stands at 19.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 0.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SOLV Debt, Balance Sheet, and Financial Health

Solventum Corp has a debt-to-equity ratio of 100.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.23x, suggesting adequate working capital coverage. Total debt on the balance sheet is $5.04B. Cash and equivalents stand at $1.64B.

SOLV has a beta of 0.99, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Solventum Corp is 72/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

Solventum Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Solventum Corp reported revenue of $8.41B and earnings per share (EPS) of $8.94. Net income for the quarter was $1.61B. Gross margin was 54.6%. Operating income came in at $2.33B.

In FY 2025, Solventum Corp reported revenue of $8.32B and earnings per share (EPS) of $8.94. Net income for the quarter was $1.56B. Gross margin was 53.5%. Revenue grew 0.9% year-over-year compared to FY 2024. Operating income came in at $2.18B.

In Q3 2025, Solventum Corp reported revenue of $2.10B and earnings per share (EPS) of $7.26. Net income for the quarter was $1.27B. Gross margin was 54.1%. Revenue grew 0.7% year-over-year compared to Q3 2024. Operating income came in at $1.69B.

In Q2 2025, Solventum Corp reported revenue of $2.16B and earnings per share (EPS) of $0.52. Net income for the quarter was $90M. Gross margin was 54.4%. Revenue grew 3.8% year-over-year compared to Q2 2024. Operating income came in at $214M.

Over the past 8 quarters, Solventum Corp has demonstrated a growth trajectory, with revenue expanding from $2.08B to $8.41B. Investors analyzing SOLV stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SOLV Dividend Yield and Income Analysis

Solventum Corp (SOLV) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SOLV Momentum and Technical Analysis Profile

Solventum Corp (SOLV) has a momentum factor score of 34/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 23/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SOLV vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Solventum Corp (SOLV) ranks #267 out of 838 stocks based on the Blank Capital composite score. This places SOLV in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SOLV against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SOLV vs S&P 500 (SPY) comparison to assess how Solventum Corp stacks up against the broader market across all factor dimensions.

SOLV Next Earnings Date

No upcoming earnings date has been announced for Solventum Corp (SOLV) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SOLV? — Investment Thesis Summary

The quantitative profile for Solventum Corp suggests caution. The value score of 77/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 34/100, a headwind for near-term performance. Low volatility (stability score 72/100) reduces downside risk.

In summary, Solventum Corp (SOLV) earns a Reduce rating with a composite score of 44.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SOLV stock.

Related Resources for SOLV Investors

Explore more research and tools: SOLV vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SOLV head-to-head with peers: SOLV vs AZN, SOLV vs SLGL, SOLV vs VMD.